Add this topic to your myFT Digest for news straight to your inbox
Logistics group can deliver to nations in sub-Saharan Africa, South America and South Asia
Pfizer confirms it will supply NHS only and reiterates confidence in supply chain
CDC head says Americans face ‘most difficult time in the public health history of this nation’
Government medical adviser says jabs could prove less effective for frail patients
Emergency use of BioNTech/Pfizer jab authorised ahead of US and EU
Russia and Italy follow with announcements, while US go-ahead could be granted soon after December 10
The surge in optimism is fully warranted but must also be accompanied by forbearance
London has authorised shot for emergency use and rollout will begin next week
Any single product has limited impact on earnings but some pharma groups stand to benefit more
BioNTech/Pfizer approval sets off race to stop spread of coronavirus
Healthcare workers and care-home residents would be initial recipients under guidance
Disruption can be uncomfortable but there are big opportunities too
European regulators due to give opinion on Pfizer/BioNTech shot on December 29 and Moderna jab on January 12
Pharma company lost patent protection for one-time blockbuster more than 4 years ago
AstraZeneca agrees $350m rights deal, Horta-Osório transfers to Credit Suisse, 2021 market predictions
The documentary’s makers talk about the challenges — human and practical — of filming in a hospital at the height of the pandemic
Neuroradiologist provoked scientists’ ire for opposing Covid-19 mitigation measures
Health officials fear Thanksgiving travel will further accelerate virus’s spread
Moderna is latest drug group to seek regulatory go-ahead for distribution in December
As the NHS prepares to roll out mass immunisation, fringe campaigners are creating doubts over safety
Biotechnology group is second western manufacturer on track to start distribution in December
Let’s be pragmatic not hysterical. Why it’s not entirely clear that a ‘no-vax, no-fly’ policy makes commercial sense for airlines. Or even for vaccine adoption.
Sectors such as energy and financial companies have made up lost ground in November
International Edition
